HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 207 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,146,832 | +157.3% | 422,692 | +142.9% | 0.03% | +166.7% |
| Q2 2023 | $6,276,141 | -20.6% | 173,999 | -15.9% | 0.01% | -25.0% |
| Q1 2023 | $7,902,426 | -42.6% | 206,924 | -14.6% | 0.02% | -42.9% |
| Q4 2022 | $13,778,845 | +28.7% | 242,159 | -10.6% | 0.03% | +16.7% |
| Q3 2022 | $10,709,000 | -10.8% | 270,921 | -0.8% | 0.02% | -4.0% |
| Q2 2022 | $12,010,000 | +86.6% | 273,028 | +69.1% | 0.02% | +127.3% |
| Q1 2022 | $6,436,000 | +135.6% | 161,431 | +137.4% | 0.01% | +175.0% |
| Q4 2021 | $2,732,000 | -11.8% | 67,992 | -10.7% | 0.00% | -20.0% |
| Q3 2021 | $3,097,000 | -24.3% | 76,166 | -15.5% | 0.01% | -28.6% |
| Q2 2021 | $4,093,000 | -54.3% | 90,175 | -58.0% | 0.01% | -56.2% |
| Q1 2021 | $8,948,000 | +7.6% | 214,667 | +10.2% | 0.02% | 0.0% |
| Q4 2020 | $8,318,000 | +57.9% | 194,823 | -2.8% | 0.02% | +45.5% |
| Q3 2020 | $5,268,000 | +17.6% | 200,529 | +19.9% | 0.01% | +10.0% |
| Q2 2020 | $4,478,000 | +87.6% | 167,218 | +26.0% | 0.01% | +66.7% |
| Q1 2020 | $2,387,000 | +27.1% | 132,747 | +25.2% | 0.01% | +100.0% |
| Q4 2019 | $1,878,000 | +23.7% | 106,020 | +8.2% | 0.00% | 0.0% |
| Q3 2019 | $1,518,000 | -38.0% | 98,003 | -31.3% | 0.00% | -40.0% |
| Q2 2019 | $2,447,000 | -30.8% | 142,630 | -35.1% | 0.01% | -28.6% |
| Q1 2019 | $3,536,000 | +2.5% | 219,693 | -6.9% | 0.01% | -12.5% |
| Q4 2018 | $3,451,000 | -0.3% | 236,082 | +23.9% | 0.01% | +14.3% |
| Q3 2018 | $3,461,000 | +14.8% | 190,565 | +6.7% | 0.01% | +16.7% |
| Q2 2018 | $3,014,000 | -54.2% | 178,604 | -46.8% | 0.01% | -45.5% |
| Q1 2018 | $6,582,000 | -43.5% | 336,023 | -40.3% | 0.01% | -45.0% |
| Q4 2017 | $11,658,000 | +407.3% | 562,961 | +325.5% | 0.02% | +400.0% |
| Q3 2017 | $2,298,000 | +39.9% | 132,293 | +3.2% | 0.00% | +33.3% |
| Q2 2017 | $1,643,000 | +238.1% | 128,136 | +241.4% | 0.00% | +200.0% |
| Q1 2017 | $486,000 | -19.3% | 37,528 | -38.0% | 0.00% | 0.0% |
| Q4 2016 | $602,000 | – | 60,524 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 7,048,282 | $126,799,000 | 27.23% |
| First Light Asset Management, LLC | 1,630,591 | $29,334,000 | 5.01% |
| SNYDER CAPITAL MANAGEMENT L P | 3,393,057 | $61,041,000 | 3.48% |
| Bellevue Group AG | 7,663,956 | $137,874,000 | 2.67% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 307,633 | $5,531,000 | 2.52% |
| Lombard Odier Asset Management (Switzerland) SA | 900,000 | $16,191,000 | 2.17% |
| Elk Creek Partners, LLC | 654,362 | $11,772,000 | 2.02% |
| DOHENY ASSET MANAGEMENT /CA | 127,110 | $2,254,000 | 1.79% |
| Granite Investment Partners, LLC | 1,277,438 | $22,981,000 | 1.49% |
| Amia Capital LLP | 69,409 | $1,249,000 | 1.11% |